Details:
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development.
Lead Product(s): Biologic Medicine
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Massachusetts Institute of Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 09, 2022